Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

A Phase II Trial Of Fractionated Vinorelbine/Doxorubicin As First-line Therapy For Advanced Breast Cancer

R. Hegg, M. A. Costa, M. Perdicaris, G. Delgado, S. Cabral-Filho, A. Malzyner, R. Caponero, N. Yamagushi, N. Novaes, A. Anelli, M. Correa, L. Nader, C. A. Andrade
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
SummaryIn western countries breast cancer is still the leading cause of death of women. Very promising results have been obtained by combining vinorelbine and doxorubicin, two of the most active drugs in metastatic breast cancer. However, despite the activity reported, this combination has shown a 10% rate of grade 2–4 cardiac toxicity, mainly due to the total cumulative doses of anthracycline delivered. The aim of this study was to divide the total dose of doxorubicin into two administrations on days 1 and 8, in order to cut down its toxicity while maintaining the same activity. Fifty-two chemotherapy naive patients with metastatic breast cancer entered into the study and were treated with vinorelbine 25 mg/m2 plus doxorubicin 25 mg/m2 both on days 1 and 8 every three weeks. Fifty-one patients were eligible and evaluable for toxicity while 47 of them were evaluable for activity. Haematological toxicity was predominantly related to neutropenia, with grade 3/4 in 16% of cycles. Non-haematological toxicity ...
This paper references
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer.
C. Nistico' (1999)
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
P. Fumoleau (1993)
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
F. Torti (1983)
Reporting results of cancer treatment
A. Miller (1981)
Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
M. Spielmann (1994)
A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5‐fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
C. Blajman (1999)
Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.
R. Chlebowski (1980)
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial.
S. Gundersen (1986)
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?
S. Bielack (1996)
A clinicopathologic analysis of adriamycin cardiotoxicity
E. Lefrak (1973)
Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.
A. Weiss (1976)
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.
J. Gehl (1996)
Navelbine (NVB), and fractionated dose doxorubicin (DX) improves first line advanced breast cancer (ABC) chemotherapy. An overview of 3 phase II trials
J. Carmichael (1997)
Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970s
M. B. Ross (1985)
Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer.
H. Hochster (1995)
Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure.
P. S. Ritch (1982)
Cancer Chemotherapy: Principles and Practice
B. Chabner (1990)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar